Online inquiry

IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4724MR)

This product GTTS-WQ4724MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL21 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001207006.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59067
UniProt ID Q9HBE4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4724MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9084MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ7598MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ1500MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-011
GTTS-WQ3909MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ5213MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ396MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ387MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ10109MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LA480
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW